220 related articles for article (PubMed ID: 22949395)
1. Description of a large family with autosomal dominant hypercholesterolemia associated with the APOE p.Leu167del mutation.
Marduel M; Ouguerram K; Serre V; Bonnefont-Rousselot D; Marques-Pinheiro A; Erik Berge K; Devillers M; Luc G; Lecerf JM; Tosolini L; Erlich D; Peloso GM; Stitziel N; Nitchké P; Jaïs JP; ; Abifadel M; Kathiresan S; Leren TP; Rabès JP; Boileau C; Varret M
Hum Mutat; 2013 Jan; 34(1):83-7. PubMed ID: 22949395
[TBL] [Abstract][Full Text] [Related]
2. APOE p.Leu167del mutation in familial hypercholesterolemia.
Awan Z; Choi HY; Stitziel N; Ruel I; Bamimore MA; Husa R; Gagnon MH; Wang RH; Peloso GM; Hegele RA; Seidah NG; Kathiresan S; Genest J
Atherosclerosis; 2013 Dec; 231(2):218-22. PubMed ID: 24267230
[TBL] [Abstract][Full Text] [Related]
3. The p.Leu167del Mutation in APOE Gene Causes Autosomal Dominant Hypercholesterolemia by Down-regulation of LDL Receptor Expression in Hepatocytes.
Cenarro A; Etxebarria A; de Castro-Orós I; Stef M; Bea AM; Palacios L; Mateo-Gallego R; Benito-Vicente A; Ostolaza H; Tejedor T; Martín C; Civeira F
J Clin Endocrinol Metab; 2016 May; 101(5):2113-21. PubMed ID: 27014949
[TBL] [Abstract][Full Text] [Related]
4. Effect of mutations in LDLR and PCSK9 genes on phenotypic variability in Tunisian familial hypercholesterolemia patients.
Slimani A; Jelassi A; Jguirim I; Najah M; Rebhi L; Omezzine A; Maatouk F; Hamda KB; Kacem M; Rabès JP; Abifadel M; Boileau C; Rouis M; Slimane MN; Varret M
Atherosclerosis; 2012 May; 222(1):158-66. PubMed ID: 22417841
[TBL] [Abstract][Full Text] [Related]
5.
Abou Khalil Y; Marmontel O; Ferrières J; Paillard F; Yelnik C; Carreau V; Charrière S; Bruckert E; Gallo A; Giral P; Philippi A; Bluteau O; Boileau C; Abifadel M; Di-Filippo M; Carrié A; Rabès JP; Varret M
Int J Mol Sci; 2022 May; 23(10):. PubMed ID: 35628605
[TBL] [Abstract][Full Text] [Related]
6. Global molecular analysis and APOE mutations in a cohort of autosomal dominant hypercholesterolemia patients in France.
Wintjens R; Bozon D; Belabbas K; MBou F; Girardet JP; Tounian P; Jolly M; Boccara F; Cohen A; Karsenty A; Dubern B; Carel JC; Azar-Kolakez A; Feillet F; Labarthe F; Gorsky AM; Horovitz A; Tamarindi C; Kieffer P; Lienhardt A; Lascols O; Di Filippo M; Dufernez F
J Lipid Res; 2016 Mar; 57(3):482-91. PubMed ID: 26802169
[TBL] [Abstract][Full Text] [Related]
7. APOE and familial hypercholesterolemia.
Civeira F; Martín C; Cenarro A
Curr Opin Lipidol; 2024 Aug; 35(4):195-199. PubMed ID: 38640077
[TBL] [Abstract][Full Text] [Related]
8. Cosegregation of serum cholesterol with cholesterol intestinal absorption markers in families with primary hypercholesterolemia without mutations in LDLR, APOB, PCSK9 and APOE genes.
Baila-Rueda L; Pérez-Ruiz MR; Jarauta E; Tejedor MT; Mateo-Gallego R; Lamiquiz-Moneo I; de Castro-Orós I; Cenarro A; Civeira F
Atherosclerosis; 2016 Mar; 246():202-7. PubMed ID: 26802983
[TBL] [Abstract][Full Text] [Related]
9. A fourth locus for autosomal dominant hypercholesterolemia maps at 16q22.1.
Marques-Pinheiro A; Marduel M; Rabès JP; Devillers M; Villéger L; Allard D; Weissenbach J; Guerin M; Zair Y; Erlich D; Junien C; Munnich A; Krempf M; Abifadel M; Jaïs JP; ; Boileau C; Varret M
Eur J Hum Genet; 2010 Nov; 18(11):1236-42. PubMed ID: 20571503
[TBL] [Abstract][Full Text] [Related]
10. APOE gene variants in primary dyslipidemia.
Khalil YA; Rabès JP; Boileau C; Varret M
Atherosclerosis; 2021 Jul; 328():11-22. PubMed ID: 34058468
[TBL] [Abstract][Full Text] [Related]
11. Autosomal dominant type IIa hypercholesterolemia: evaluation of the respective contributions of LDLR and APOB gene defects as well as a third major group of defects.
Saint-Jore B; Varret M; Dachet C; Rabès JP; Devillers M; Erlich D; Blanchard P; Krempf M; Mathé D; Chanu B; Jacotot B; Farnier M; Bonaïti-Péllié C; Junien C; Boileau C
Eur J Hum Genet; 2000 Aug; 8(8):621-30. PubMed ID: 10952765
[TBL] [Abstract][Full Text] [Related]
12. Reduced penetrance of autosomal dominant hypercholesterolemia in a high percentage of families: importance of genetic testing in the entire family.
Garcia-Garcia AB; Ivorra C; Martinez-Hervas S; Blesa S; Fuentes MJ; Puig O; Martín-de-Llano JJ; Carmena R; Real JT; Chaves FJ
Atherosclerosis; 2011 Oct; 218(2):423-30. PubMed ID: 21868016
[TBL] [Abstract][Full Text] [Related]
13. Spectrum of mutations and phenotypic expression in patients with autosomal dominant hypercholesterolemia identified in Italy.
Bertolini S; Pisciotta L; Rabacchi C; Cefalù AB; Noto D; Fasano T; Signori A; Fresa R; Averna M; Calandra S
Atherosclerosis; 2013 Apr; 227(2):342-8. PubMed ID: 23375686
[TBL] [Abstract][Full Text] [Related]
14. Lipid phenotype and heritage pattern in families with genetic hypercholesterolemia not related to LDLR, APOB, PCSK9, or APOE.
Jarauta E; Pérez-Ruiz MR; Pérez-Calahorra S; Mateo-Gallego R; Cenarro A; Cofán M; Ros E; Civeira F; Tejedor MT
J Clin Lipidol; 2016; 10(6):1397-1405.e2. PubMed ID: 27919357
[TBL] [Abstract][Full Text] [Related]
15. New Sequencing technologies help revealing unexpected mutations in Autosomal Dominant Hypercholesterolemia.
Elbitar S; Susan-Resiga D; Ghaleb Y; El Khoury P; Peloso G; Stitziel N; Rabès JP; Carreau V; Hamelin J; Ben-Djoudi-Ouadda A; Bruckert E; Boileau C; Seidah NG; Varret M; Abifadel M
Sci Rep; 2018 Jan; 8(1):1943. PubMed ID: 29386597
[TBL] [Abstract][Full Text] [Related]
16. Plasma lipoprotein(a) levels in patients with homozygous autosomal dominant hypercholesterolemia.
Sjouke B; Yahya R; Tanck MWT; Defesche JC; de Graaf J; Wiegman A; Kastelein JJP; Mulder MT; Hovingh GK; Roeters van Lennep JE
J Clin Lipidol; 2017; 11(2):507-514. PubMed ID: 28502508
[TBL] [Abstract][Full Text] [Related]
17. Lipid-lowering response in subjects with the p.(Leu167del) mutation in the APOE gene.
Bea AM; Lamiquiz-Moneo I; Marco-Benedí V; Mateo-Gallego R; Pérez-Calahorra S; Jarauta E; Martín C; Cenarro A; Civeira F
Atherosclerosis; 2019 Mar; 282():143-147. PubMed ID: 30731287
[TBL] [Abstract][Full Text] [Related]
18. Increased intestinal cholesterol absorption in autosomal dominant hypercholesterolemia and no mutations in the low-density lipoprotein receptor or apolipoprotein B genes.
García-Otín AL; Cofán M; Junyent M; Recalde D; Cenarro A; Pocoví M; Ros E; Civeira F
J Clin Endocrinol Metab; 2007 Sep; 92(9):3667-73. PubMed ID: 17566095
[TBL] [Abstract][Full Text] [Related]
19. Phenotypic variability in 4 homozygous familial hypercholesterolemia siblings compound heterozygous for LDLR mutations.
Rabacchi C; Bigazzi F; Puntoni M; Sbrana F; Sampietro T; Tarugi P; Bertolini S; Calandra S
J Clin Lipidol; 2016; 10(4):944-952.e1. PubMed ID: 27578127
[TBL] [Abstract][Full Text] [Related]
20. Identification and characterization of new gain-of-function mutations in the PCSK9 gene responsible for autosomal dominant hypercholesterolemia.
Abifadel M; Guerin M; Benjannet S; Rabès JP; Le Goff W; Julia Z; Hamelin J; Carreau V; Varret M; Bruckert E; Tosolini L; Meilhac O; Couvert P; Bonnefont-Rousselot D; Chapman J; Carrié A; Michel JB; Prat A; Seidah NG; Boileau C
Atherosclerosis; 2012 Aug; 223(2):394-400. PubMed ID: 22683120
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
